The primary objective of the Phase I/II, dose escalation study is to determine the safety, maximum tolerated dose and objective response rate of GRN163L when administered intravenously in combination with a paclitaxel/bevacizumab regimen in this patient population. The current study is the fifth clinical trial of GRN163L.
Fabio Benedetti, chief medical officer of oncology at Geron, said: “This is an important milestone in the clinical development of our lead anticancer drug. Extending the clinical testing of GRN163L to breast cancer reflects the potentially broad and important role of telomerase in fighting cancer.”